Patents by Inventor Martin Schwill

Martin Schwill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • A COMBINATION OF A CBP/P300 BROMODOMAIN INHIBITOR AND AN EGFR INHIBITOR FOR USE IN TREATING EGFR-MUTANT NSCLC
    Publication number: 20230255966
    Abstract: The present invention is inter alia concerned with a combination of a CBP/p300 bromodomain inhibitor and an EGFR inhibitor for use in the treatment of a patient suffering from NSCLC, wherein the NSCLC exhibits an oncogenic alteration in the EGFR.
    Type: Application
    Filed: June 24, 2021
    Publication date: August 17, 2023
    Applicant: TOLREMO THERAPEUTICS AG
    Inventors: Stefanie Flückiger-Mangual, Dorothea Gruber, Thomas Bohnacker, Martin Schwill, Debora Schmitz-Rohmer, Charles-Henry Fabritius, Sara Laudato
  • COMBINATION OF A CBP/P300 BROMODOMAIN INHIBITOR AND A KRAS INHIBITOR FOR THE TREATMENT OF CANCER
    Publication number: 20230233558
    Abstract: The present invention is inter alia concerned with (i) a combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for use in the treatment of a patient suffering from cancer, wherein the cancer exhibits an oncogenic alteration in the KRAS; (ii) a kit comprising (a) a pharmaceutical dosage form comprising a CBP/p300 bromodomain inhibitor and (b) a pharmaceutical dosage form comprising a KRAS inhibitor, and (iii) a pharmaceutical dosage form comprising a CBP/p300 bromodomain inhibitor and a a KRAS inhibitor.
    Type: Application
    Filed: June 24, 2021
    Publication date: July 27, 2023
    Applicant: TOLREMO THERAPEUTICS AG
    Inventors: Stefanie Flückiger-Mangual, Dorothea Gruber, Thomas Bohnacker, Martin Schwill, Debora Schmitz-Rohmer, Charles-Henry Fabritius, Sara Laudato
  • Bispecific HER2 Ligands for Cancer Therapy
    Publication number: 20220135700
    Abstract: The invention relates to a bispecific HER2-targeting agent that includes (a) a first polypeptide ligand that binds to HER2 extracellular domain 1, (b) a second polypeptide ligand that binds to HER2 extracellular domain 4, and (c) a linker covalently attaching said first polypeptide ligand to said second polypeptide ligand.
    Type: Application
    Filed: January 17, 2022
    Publication date: May 5, 2022
    Applicant: UNIVERSITÄT ZÜRICH
    Inventors: Andreas Plückthun, Florian Kast, Martin Schwill, Annemarie Honegger, Rastislav Tamaskovic, Christian Jost
  • HER2-BINDING TETRAMERIC POLYPEPTIDES
    Publication number: 20210395396
    Abstract: The invention relates to a tetrameric polypeptide comprising a first polypeptide chain comprising a first VL antigen binding domain and a first CL constant domain, a second polypeptide chain comprising a first VH antigen binding domain, a first CH1 constant domain, a first CH2 constant domain and a first CH3 constant domain, a first ligand binding to a HER2 D4 epitope linked to the N-terminus of said first VL antigen binding domain or said first VH antigen binding domain by a first interdomain amino acid linker, a third polypeptide chain comprising a second VL antigen binding domain and a second CL constant domain, a fourth polypeptide chain comprising a second VH antigen binding domain, a second CH1 constant domain, a second CH2 constant domain and a second CH3 constant domain and a third ligand binding to a HER2 D4 epitope linked to the N-terminus of said second VL antigen binding domain or said second VH antigen binding domain by a second interdomain amino acid linker, wherein the VL antigen binding domain
    Type: Application
    Filed: October 8, 2019
    Publication date: December 23, 2021
    Applicant: UNIVERSITÄT ZÜRICH
    Inventors: Florian KAST, Martin SCHWILL, Annemarie HONEGGER, Jakob STÜBER, Rastislav TAMASKOVIC, Andreas PLÜCKTHUN
  • Bispecific HER2 Ligands for Cancer Therapy
    Publication number: 20190127481
    Abstract: The invention relates to a bispecific HER2-targeting agent that includes (a) a first polypeptide ligand that binds to HER2 extracellular domain 1, (b) a second polypeptide ligand that binds to HER2 extracellular domain 4, and (c) a linker covalently attaching said first polypeptide ligand to said second polypeptide ligand.
    Type: Application
    Filed: October 8, 2018
    Publication date: May 2, 2019
    Applicant: UNIVERSITÄT ZÜRICH
    Inventors: Andreas Plückthun, Florian Kast, Martin Schwill, Annemarie Honegger, Rastislav Tamaskovic, Christian Jost
  • Bispecific HER2 ligands for cancer therapy
    Patent number: 10093740
    Abstract: The invention relates to a bispecific HER2-targeting agent comprising a.) a first polypeptide ligand that binds to HER2 extracellular domain 1, b.) a second polypeptide ligand that binds to HER2 extracellular domain 4 and c.) a linker covalently attaching said first polypeptide ligand to said second polypeptide ligand.
    Type: Grant
    Filed: October 14, 2013
    Date of Patent: October 9, 2018
    Assignee: Universitat Zurich
    Inventors: Rastislav Tamaskovic, Martin Schwill, Andreas Pluckthun, Christian Jost
  • BISPECIFIC HER2 LIGANDS FOR CANCER THERAPY
    Publication number: 20150284463
    Abstract: The invention relates to a bispecific HER2-targeting agent comprising a.) a first polypeptide ligand that binds to HER2 extracellular domain 1, b.) a second polypeptide ligand that binds to HER2 extracellular domain 4 and c.) a linker covalently attaching said first polypeptide ligand to said second polypeptide ligand.
    Type: Application
    Filed: October 14, 2013
    Publication date: October 8, 2015
    Applicant: UNIVERSITAT ZURICH PROREKTORAT MNW
    Inventors: Rastislav Tamaskovic, Martin Schwill, Andreas Pluckthun, Christian Jost